Procter & Gamble Co. (NYSE: PG)

1Company Overview & Business Model

P&G is a global consumer staples leader focused on daily-use categories across five operating sectors: Beauty; Grooming; Health Care; Fabric & Home Care; Baby, Feminine & Family Care. E-commerce is material and growing (≈19% of sales in FY25). P&G's portfolio strategy emphasizes superiority (product, package, brand, retail execution, value), productivity, "constructive disruption," and an agile organization.

Flagship Brands

Tide Ariel Dawn Febreze Gillette Braun Pampers Always Bounty Charmin Crest Oral-B Olay

Scale & Performance (FY25)

$84.3B

Net Sales (flat YoY)

+2%

Organic Sales Growth

+4%

Core EPS Growth

9 of 10

Categories Growing

Fabric & Home Care is the largest sector (~36% of earnings in FY25).

💪Strengths

Category leadership & brands: #1 or #2 shares in most categories (e.g., >35% share in Fabric Care; ~30% in Oral Care). Deep brand equity and pricing power.
Execution & cash returns: FY25 core EPS +4%, free-cash-flow productivity 87%; $16B returned to shareholders ($9.9B dividends, $6.5B buybacks). 69th consecutive annual dividend increase in April 2025.
Balance sheet quality: Large, diversified cash flows; AA- long-term rating affirmed by S&P in Jan-2025; Moody's performed a periodic review in Sept-2025 (ratings unchanged).
Productivity engine: Ongoing cost savings in SG&A and COGS supported Q4 margin expansion; FY25 saw notable productivity offsets to commodity/tariff headwinds.
Omnichannel reach: E-commerce +12% in FY25, now ~19% of sales.

⚠️Weaknesses / Watch-Items

Macro & FX drag: FY25 all-in sales flat; +1% price was offset by ~-1% FX. Some categories (e.g., Baby Care) experienced volume pressure in North America and IMEA.
Restructuring & overhead reset: Announced FY25 portfolio/productivity plan with $1.0–$1.6B non-core restructuring over two years and up to ~7,000 non-manufacturing role reductions by FY27—execution risk and near-term non-core charges.
Customer concentration: Walmart ~16% of consolidated net sales in FY25—gives large retailers negotiation leverage.
China sensitivities: Beauty (e.g., SK-II) and Oral Care in China remain volatile; category and competitive dynamics can weigh on mix.

⚡Key Risks & Impact Assessment

Medium

Regulatory/Trade & Tariff Risk

Higher tariffs increased costs (Q4 core gross margin included ~40 bps tariff headwind). Escalating trade actions could pressure margins and pricing.

Medium

Commodity Inflation

Pulp, resins, surfactants and energy are meaningful inputs; adverse moves pressure gross margin despite productivity offsets.

Medium

FX & Macro Slowdown

EM and Europe currency/macro volatility can neutralize pricing gains, limiting top-line growth. FY25 FX offset pricing.

Medium/High

Competition & Private Label

Intense rivalry with global peers and retailer brands—especially in paper and basic cleaners—can compress price/mix.

Medium

Concentration/Customer Power

Walmart (~16% of sales) and other mega-retailers can influence shelf, promotion and terms.

Medium

Reorg Execution Risk

The multi-year productivity program (incl. workforce reductions) must hit savings without hurting innovation or in-market execution.

🎯Competitors & Landscape

Core Global Peers:

Colgate-Palmolive (CL), Kimberly-Clark (KMB), Unilever (UL/UNA), Reckitt (RKT), Church & Dwight (CHD); category-specific rivals include L'Oréal (Beauty) and Edgewell (Grooming).

How P&G Differentiates:

Breadth of brands, trade-up innovation, superior product performance, and scale-driven productivity. Where it can lag: exposure to tariff/FX, category slowdowns (Baby, some Beauty SKUs), and retailer leverage.

Quick Relative Snapshot (TTM multiples, late Sept-2025)

Company	P/E Ratio	P/S Ratio	Key Focus
P&G	~22.3x	~4.4x	Diversified staples leader
Colgate-Palmolive	~22.2x	~3.4x	Oral care & personal care
Kimberly-Clark	~17.5x	~2.1x	Tissue & personal care
Church & Dwight	~25.2x	-	Household & personal care

Interpretation: PG trades at a premium to staples on sales and roughly in-line with top-tier peers on P/E, reflecting quality, brand equity and cash consistency.

📈Growth Potential

Historical Performance:

FY25 organic +2%, 9/10 categories up; 39th consecutive quarter of top-line growth in Q4.

FY26 Guidance:

+1% to +5%

All-in Sales Growth

Flat to +4%

Organic Sales Growth

~$10B

Planned Dividends

~$5B

Planned Buybacks

Core ETR ~20–21%; capex 4–5% of sales.

Forward Drivers:

Premiumization & innovation: Trade-up SKUs (e.g., premium detergents, brushes, grooming systems) and productivity-funded reinvestment
Channel: E-commerce mix rising (19%) and still compounding
Geography/category cleanup: Portfolio pruning (brand/product form discontinuations are a 30–50 bps FY26 headwind) improves focus and ROI over time

Acquisition target? Unlikely—PG's $350B+ market value, AA- balance sheet and global scale make it a consolidator/partner, not a realistic target.

💰Valuation Analysis

Relative Valuation

PG @ ~$152.5: P/E ~22–23x, P/S ~4.4x, P/B ~6.9x. Versus peers: premium to KMB and near CL on P/E; premium on P/S consistent with PG's margins/brand strength. On this basis, PG screens fairly valued to modestly premium to large-cap staples.

Absolute Valuation (Two Lenses)

Dividend Discount (Gordon) – Base Case:

≈$4.23/sh

Current Annual Dividend (after $1.0568 quarterly increase)

4.5–5.0%

Long-run Dividend Growth

8.5–9.0%

Cost of Equity (low beta)

$125–$145

Intrinsic Value Range (next-year dividend basis)

Result: Conservative DDM tilts below spot, reflecting today's low dividend yield vs growth.

Earnings-Power Multiple:

FY25 core EPS $6.83; FY26 core EPS $6.83–$7.09 (midpoint $6.96)
Applying 20–23x (quality staples range) implies $140–$160 fair value (midpoint ≈ $150)

💎 Valuation Takeaway

Blending both methods, we estimate intrinsic value ≈ $140–$155. At ~$152, PG is around fair value with a defensive, cash-compounder profile.

🏆Overall Quality Conclusion

P&G remains a high-quality, wide-moat staples compounder: durable brands, scale, and disciplined productivity fund steady reinvestment and dependable cash returns. FY25 results and FY26 guide point to steady—not spectacular—growth, with tariff/FX and category mix as near-term headwinds. Balance sheet strength (AA-), shareholder returns, and resilient demand support low beta, long-duration defensiveness.

📊Investment & Trading Strategy

🎯 HOLD (Core Long-term Investors) / BUY on Weakness

Rationale: Shares sit near our blended fair value band ($140–$155). Upside exists if FY26 organic growth surprises toward the high end and productivity offsets outpace tariffs/commodities; downside buffered by dividend/buybacks.

Suggested Levels (as of 09/26/2025):

Entry Points (Long-term)

$148–$152: Near 52-week support $149.9 and just below the 50-DMA ~$156; scale in on broader staples pullbacks

Tactical Adds (Traders)

Pullbacks toward $150: Oversold bounces when RSI < 35–40. (Current RSI ~38–39)

Risk Management

Initial stop ~$145: (≈5% below entry) to respect 52-week support breaks; trail stops as price approaches targets

Exit/Targets:

Near-term: Reversion to 50-DMA ~$156
3–6 months: Test 200-DMA ~$161–$163 if staples sentiment improves
12 months (base case): $160 (≈23x FY26 EPS midpoint)

Time Horizons:

Traders: Weeks to months, trade the 50/200-DMA band
Investors: 3–5 years+; reinvest dividends, add on macro/tariff-driven dips

Catalysts

🚀 Upside Catalysts

FY26 organic growth toward +4%
Mix premiumization
Faster e-commerce growth
Accelerated buybacks (~$5B planned)
Commodity relief

📉 Downside Catalysts

Tariff escalation
FX headwinds
China category weakness (Beauty/Oral)
Large-retailer pricing pressure (Walmart concentration)
Execution shortfall on restructuring savings